<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bilton, Diana</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">LAI Improves Pulmonary Function in CF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-23</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment of chronic bronchopulmonary infection by Pseudomonas aeruginosa in patients with cystic fibrosis (CF) with liposomal amikacin for inhalation (LAI) resulted in improved pulmonary function and decreased P aeruginosa sputum concentration in an interim analysis. This article discusses interim data from the Long Term Safety and Tolerability of Open-Label Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients With Chronic Infection due to Pseudomonas aeruginosa trial [CLEAR-110; NCT01316276; Bilton D et al. Am J Respir Crit Care Med 2014].</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>